Get access

Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users

Authors

  • D. A. M. C. Van De Vijver,

    1. Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands,
    Search for more papers by this author
  • R. A. C. Roos,

    1. Department of Neurology, Leiden University Medical Centre (LUMC), Leiden University, Leiden, the Netherlands,
    Search for more papers by this author
  • P. A. F. Jansen,

    1. Department of Geriatric Medicine, University Medical Centre Utrecht (UMCU), Utrecht University, Utrecht, the Netherlands
    Search for more papers by this author
  • A. J. Porsius,

    1. Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands,
    Search for more papers by this author
  • A. De Boer

    1. Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands,
    Search for more papers by this author

David van de Vijver Department of pharmaco-epidemiology and -therapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, PO Box 80 082, 3508 TB Utrecht, the Netherlands Tel.: +31 30 253 73 24 Fax: +31 30 253 91 66 e-mail: d.a.m.c.vandevijver@pharm.uu.nl

Abstract

Objectives– Animal studies showed that benzodiazepines decrease the concentration of dopamine in the striatum. Benzodiazepines may therefore affect the treatment of Parkinson’s disease. This study determined whether start of a benzodiazepine in patients on levodopa was followed by a faster increase of antiparkinsonian drug treatment. Methods– Data came from the PHARMO database, which includes information on drug dispensing for all residents of six Dutch cities. Selected were all patients aged 55 years and older who used levodopa for at least 360 days. The rate of increase of antiparkinsonian drug treatment was compared between starters of a benzodiazepine and controls who did not start a benzodiazepine with the use of Cox’s proportional hazard model. Results– Identified were 45 benzodiazepine starters (27 women, mean age 76.4 years) and 169 controls (83 women, 74.3 years). Antiparkinsonian drug treatment increased faster in the benzodiazepine group; relative risk was 1.44 (95% confidence interval 0.80–2.59). Conclusion– This study has not found any statistically significant increase in antiparkinsonian drug treatment when a benzodiazepine was started in a small population of chronic levodopa users.

Ancillary